Pharmacological cognitive enhancement: Treatment of neuropsychiatric disorders and lifestyle use by healthy people

The Lancet Psychiatry

Volumn 2, Issue 4, 2015, Pages 357-362

  Sahakian, Barbara J ^a   Morein Zamir, Sharon ^b,c  

^a Department of Psychiatry ^*  (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; METHYLPHENIDATE; MODAFINIL; BENZHYDRYL DERIVATIVE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BEHAVIOR; COGNITION; DYSPHASIA; HUMAN; LIFESTYLE MODIFICATION; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPSYCHIATRIC DISORDER; NOTE; COGNITION DISORDERS; DRUG EFFECTS; LIFESTYLE;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENZHYDRYL COMPOUNDS; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; HUMANS; LIFE STYLE; METHYLPHENIDATE; NOOTROPIC AGENTS;

EID: 84926488220     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(15)00004-8     Document Type: Note

References (67)

1. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012, 366:893-903.
2. Zohar J, Nutt DJ, Kupfer DJ, et al. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol 2014, 24:1005-1014.
3. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: technology appraisal guidance [TA98] National Institute for Health and Care Excellence (NICE), (accessed Feb 20, 2015). http://www.nice.org.uk/guidance/ta98.
4. Green MF Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006, 67(suppl 9):3-8.
5. Beddington J, Cooper CL, Field J, et al. The mental wealth of nations. Nature 2008, 455:1057-1060.
6. Salokangas RK, McGlashan TH Early detection and intervention of psychosis. A review. Nord J Psychiatry 2008, 62:92-105.
7. Kennedy N, Foy K, Sherazi R, McDonough M, McKeon P Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord 2007, 9:25-37.
8. Sahakian BJ, Malloch G, Kennard C A UK strategy for mental health and wellbeing. Lancet 2010, 375:1854-1855.
9. Morein-Zamir S, Robbins TW Fronto-striatal circuits in response-inhibition: relevance to addiction. Brain Res 2014, published online Sept 16. 10.1016/j.brainres.2014.09.012.
10. Sahakian BJ What do experts think we should do to achieve brain health?. Neurosci Biobehav Revs 2014, 43:240-258.
11. Morein-Zamir S, Sahakian BJ Pharmaceutical cognitive enhancement. Oxford Handbook of Neuroethics 2011, Oxford University Press, Oxford. J. Illes, B.J. Sahakian (Eds.).
12. Morein-Zamir S, Robbins TW, Turner DC, Sahakian BJ Pharmacological cognitive enahcnement. Mental capital and mental wellbeing project 2010, 129-138. Wiley-Blackwell, Oxford. C.L. Cooper, J. Field, U. Goswami, R. Jenkins, B.J. Sahakian (Eds.).
13. Sahakian BJ, Morein-Zamir S Professor's little helper. Nature 2007, 20:1157-1159.
14. Repantis D, Schlattmann P, Laisney O, Heuser I Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010, 62:187-206.
15. Scoriels L, Barnett JH, Soma PK, Sahakian BJ, Jones PB Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology 2012, 220:249-258.
16. Scoriels L, Barnett JH, Murray GK, et al. Effects of modafinil on emotional processing in first episode psychosis. Biol Psychiatry 2011, 69:457-464.
17. Ilieva IP, Farah MJ Enhancement stimulants: perceived motivational and cognitive advantages. Front Neurosci 2013, 7:198.
18. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011, 168:472-485.
19. Volkow ND, Baler RD, Goldstein RZ Addiction: pulling at the neural threads of social behaviors. Neuron 2011, 69:599-602.
20. Husain M, Mehta MA Cognitive enhancement by drugs in health and disease. Trends Cogn Sci 2011, 15:28-36.
21. Muller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian BJ Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology 2013, 64:490-495.
22. Volkow ND, Wang GJ, Kollins SH, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009, 302:1084-1091.
23. Aharonovich E, Amrhein PC, Bisaga A, Nunes EV, Hasin DS Cognition, commitment language, and behavioral change among cocaine-dependent patients. Psychol Addict Behav 2008, 22:557-562.
24. Goss AJ, Kaser M, Costafreda S, Sahakian BJ, Fu CHY Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2013, 74:1101-1107.
25. Morgan PT, Pace-Schott E, Pittman B, Stickgold R, Malison RT Normalizing effects of modafinil on sleep in chronic cocaine users. Am J Psychiatry 2010, 167:331-340.
26. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205-211.
27. Economidou D, Pelloux Y, Robbins TW, Dalley JW, Everitt BJ High impulsivity predicts relapse to cocaine-seeking after punishment-induced abstinence. Biol Psychiatry 2009, 65:851-856.
28. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008, 47:21-31.
29. Schermer M, Bolt I, de Jongh R, Olivier B The future of psychopharmacological enhancements: expectations and policies. Neuroethics 2009, 2:75-87.
30. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011, 69:e145-e157.
31. Scoriels L, Jones PB, Sahakian BJ Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology 2013, 64:168-184.
32. Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiatry 2012, 71:538-544.
33. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat 2012, 43:303-312.
34. Arnsten AF Stress impairs prefrontal cortical function in rats and monkeys: role of dopamine D1 and norepinephrine alpha-1 receptor mechanisms. Prog Brain Res 2000, 126:183-192.
35. Ramos BP, Arnsten AF Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 2007, 113:523-536.
36. Maier LJ, Liechti ME, Herzig F, Schaub MP To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students. PLoS One 2013, 8:e77967.
37. Elliott GR, Elliott MD Pharmacological cognitive enhancers: comment on Smith and Farah (2011). Psychol Bull 2011, 137:749-750.
38. Sahakian BJ, Labuzetta JN Bad moves: how decision making goes wrong and the ethics of smart drugs 2013, Oxford University Press, Oxford.
39. Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006, 26:1501-1510.
40. Smith ME, Farah MJ Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull 2011, 137:717-741.
41. Sussman S, Pentz MA, Spruijt-Metz D, Miller T Misuse of "study drugs:" prevalence, consequences, and implications for policy. Subst Abuse Treat Prev Pol 2006, 1:15.
42. Franke AG, Bonertz C, Christmann M, et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2011, 44:60-66.
43. Johnston LD, O'Malley PM, Miech RA, Bachman JG, Schulenberg JE Monitoring the future national results on drug use 1975-2013: overview, key findings on adolescent drug use 2013, Institute for Social Research, the University of Michigan, Ann Arbor.
44. Ragan CI, Bard I, Singh I What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology 2013, 64:588-595.
45. Sears DO College sophomores in the laboratory: influences of a narrow data base on social psychology's view of human nature. J Pers Soc Psychol 1986, 51:515-530.
46. Franke AG, Bagusat C, Dietz P, et al. Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med 2013, 11:102.
47. Michalopoulou PG, Lewis SW, Wykes T, Jaeger J, Kapur S Treating impaired cognition in schizophrenia: the case for combining cognitive-enhancing drugs with cognitive remediation. Eur Neuropsychopharmacol 2013, 23:790-798.
48. Berthier ML, Pulvermuller F, Davila G, Casares NG, Gutierrez A Drug therapy of post-stroke aphasia: a review of current evidence. Neuropsychol Rev 2011, 21:302-317.
49. Norberg MM, Krystal JH, Tolin DF A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008, 63:1118-1126.
50. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004, 61:1136-1144.
51. Insel TR, Sahakian BJ, Voon V, et al. Drug Research: a plan for mental illness. Nature 2012, 483:269.
52. Insel TR, Voon V, Nye JS, et al. Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev 2013, 37:2438-2444.
53. Schueller SM, Munoz RF, Mohr DC Realizing the potential of behavioral intervention technologies. Curr Dir Psychol Sci 2013, 22:478-483.
54. Banjo OC, Nadler R, Reiner PB Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. PLoS One 2010, 5:e14322.
55. Franke AG, Papenburg C, Schotten E, Reiner PB, Lieb K Attitudes towards prescribing cognitive enhancers among primary care physicians in Germany. BMC Fam Pract 2014, 15:3.
56. Singh I, Kelleher KJ Neuroenhancement in young people: proposal for research, policy, and clinical management. AJOB Neurosci 2010, 1:3-16.
57. Sahakian BJ, Morein-Zamir S Neuroethical issues in cognitive enhancement. J Psychopharmacol 2011, 25:197-204.
58. Chatterjee A Cosmetic neurology: the controversy over enhancing movement, mentation, and mood. Neurology 2004, 28:968-974.
59. Kaye S, Darke S The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care?. Addiction 2012, 107:467-477.
60. CQC annual report and accounts Care Quality Commissson, (accessed Feb 20, 2015). http://www.cqc.org.uk/content/cqc-annual-report-201213.
61. Human enhancement and the future of work The Academy of Medical Sciences, (accessed Oct 14, 2014). http://www.acmedsci.ac.uk/policy/policy/human-enhancement-and-the-future-of-work/.
62. Greely H, Sahakian B, Harris J, et al. Towards responsible use of cognitive enhancing drugs in the healthy. Nature 2008, 456:702-705.
63. Dubljevic V Prohibition or coffee shops: regulation of amphetamine and methylphenidate for enhancement use by healthy adults. Am J Bioeth 2013, 13:23-33.
64. Dresser R, Frader J Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics 2009, 37:476-486.
65. Evans BJ Distinguishing product and practice regulation in personalized medicine. Clin Pharmacol Ther 2007, 81:288-293.
66. Zito JM, Derivan AT, Kratochvil CJ, Safer DJ, Fegert JM, Greenhill LL Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health 2008, 2:24.
67. Califano J "You've got drugs!" V: prescription drug pushers on the internet 2008, The National Center on Addiction and Substance at Columbia University, New York.